A Phase II Evaluation of Paclitaxel (Taxol, NSC 673089) and Carboplatin (Paraplatin, NSC 241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma.

Trial Profile

A Phase II Evaluation of Paclitaxel (Taxol, NSC 673089) and Carboplatin (Paraplatin, NSC 241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2010

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 17 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Aug 2010 Results will be presented in the Journal of Clinical Oncology according to a Gynecologic Oncology Group (GOG) report.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top